The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
ACADEMIA
Camostat Potential Treatment for COVID-19: German Study
The serine protease inhibitor camostat mesylate could have the potential to be used as a treatment for COVID-19, according to results from an in vitro study conducted by a German research group using a human cell line to identify the…
To read the full story
Related Article
- Drug Makers Restricting Nafamostat Supplies as Hopes Grow for Its Repurposing for COVID-19
April 22, 2020
- Ono Curbing Camostat Supplies after Drug Reported as Potential COVID-19 Hopeful
April 15, 2020
- Japan Plans Alvesco Clinical Trial for Coronavirus
March 24, 2020
- Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
March 19, 2020
ACADEMIA
- Taking on Solid Tumors - 1: Japan Sees Rush of Bispecific Approvals with Good Progress in Blood Cancers, and More
May 27, 2025
- Japan Consortium to Promote Domestic R&D of Cannabis-Derived Meds
May 14, 2025
- CGP Test Data for Over 100,000 Patients Now on National Database
May 13, 2025
- Diabetes Society Flags DKA Risk for AstraZeneca’s Truqap after Report of Death
April 21, 2025
- iPSC-Derived Cells Effective in Parkinson’s, Approval Could Come in FY2025
April 21, 2025
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…